<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>XOPENEX- levalbuterol hydrochloride solution </strong><br>Akorn, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use XOPENEX<span class="Sup">®</span> Inhalation Solution safely and effectively. See full prescribing information for XOPENEX<span class="Sup">®</span> Inhalation Solution.<br>XOPENEX<span class="Sup">®</span> (levalbuterol hydrochloride) Inhalation Solution, for inhalation use <br>Initial U.S. Approval: 1999
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">XOPENEX (levalbuterol hydrochloride) Inhalation Solution is a beta<span class="Sub">2</span>-adrenergic agonist indicated for:
 </p>
<ul class="Disc"><li>Treatment or prevention of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. (<a href="#s1">1</a>)
</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>FOR ORAL INHALATION ONLY (<a href="#s2">2</a>)
</li>
<li>
<span class="Italics">Children 6-11 years old:</span> 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day. (<a href="#s2">2</a>)
</li>
<li>
<span class="Italics">Adults and Adolescents ≥12 years old:</span> 0.63 mg administered three times a day, every 6 to 8 hours, by nebulization. The maximum recommended dose is 1.25 mg three times a day. (<a href="#s2">2</a>)
</li>
<li>For use with a standard jet nebulizer (with a face mask or mouthpiece) connected to an air compressor. (<a href="#s2">2</a>)
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Inhalation Solution (unit-dose vial for nebulization): 0.31 mg/3 mL, 0.63 mg/3 mL and 1.25 mg/3 mL. (<a href="#s3">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to levalbuterol or racemic albuterol. (<a href="#s4">4</a>)
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Life-threatening <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span> may occur. Discontinue XOPENEX Inhalation Solution immediately and treat with alternative therapy. (<a href="#s6">5.1</a>)
</li>
<li>Need for more doses of XOPENEX Inhalation Solution than usual may be a sign of deterioration of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and requires reevaluation of treatment. (<a href="#s7">5.2</a>)
</li>
<li>XOPENEX Inhalation Solution is not a substitute for corticosteroids. (<a href="#s8">5.3</a>)
</li>
<li>Cardiovascular effects may occur. Consider discontinuation of XOPENEX Inhalation Solution if these effects occur. Use with caution in patients with underlying <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>. (<a href="#s9">5.4</a>)
</li>
<li>Excessive use may be fatal. Do not exceed recommended dose. (<a href="#s10">5.5</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span> may occur. Discontinue XOPENEX Inhalation Solution immediately. (<a href="#s11">5.6</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and changes in blood glucose may occur. (<a href="#s12">5.7</a>, <a href="#s13">5.8</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions are: <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>. (<a href="#s14">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Akorn, Inc. at 1-800-932-5676 or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics">www.fda.gov/medwatch</span><span class="Bold">.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Other short-acting sympathomimetic aerosol bronchodilators and adrenergic drugs: May potentiate effect. (<a href="#s20">7.1</a>)
</li>
<li>Beta-blockers: May block bronchodilatory effects of beta-agonists and produce severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> should not normally be treated with beta-blockers. (<a href="#s21">7.2</a>)
</li>
<li>Diuretic: May worsen electrocardiographic changes or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> associated with diuretic may worsen. Consider monitoring potassium levels. (<a href="#s22">7.3</a>)
</li>
<li>Digoxin: May decrease serum digoxin levels. Consider monitoring digoxin levels. (<a href="#s23">7.4</a>)
</li>
<li>Monoamine oxidase inhibitors (MAOs) or tricyclic antidepressants: May potentiate effect of albuterol on the cardiovascular system. (<a href="#s24">7.5</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical Bronchospasm</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Deterioration of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use of Anti-Inflammatory Agents
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Cardiovascular Effects
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Do Not Exceed Recommended Dose
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate Hypersensitivity Reactions</span>
</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Coexisting Conditions
</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Short-Acting Bronchodilators
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Beta-blockers
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Diuretics
</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Digoxin
</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use
</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics
</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">XOPENEX (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">XOPENEX Inhalation Solution is for oral inhalation only. Administer by nebulization using with a standard jet nebulizer (with a face mask or mouthpiece) connected to an air compressor. Do not exceed recommended dose.
</p>
<p><span class="Italics">Children 6-11 years old:</span> The recommended dosage of XOPENEX Inhalation Solution for patients 6-11 years old is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day.
</p>
<p><span class="Italics">Adults and Adolescents ≥12 years old:</span> The recommended starting dosage of XOPENEX Inhalation Solution for patients 12 years of age and older is 0.63 mg administered three times a day, every 6 to 8 hours, by nebulization.
</p>
<p>Patients 12 years of age and older with more severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or patients who do not respond adequately to a dose of 0.63 mg of XOPENEX Inhalation Solution may benefit from a dosage of 1.25 mg three times a day.
</p>
<p>Patients receiving the highest dose of XOPENEX Inhalation Solution should be monitored closely for adverse systemic effects, and the risks of such effects should be balanced against the potential for improved efficacy.
</p>
<p>The use of XOPENEX Inhalation Solution can be continued as medically indicated to help control recurring bouts of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. During this time, most patients gain optimal benefit from regular use of the inhalation solution.
</p>
<p>If a previously effective dosage regimen fails to provide the usual response this may be a marker of destabilization of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.
</p>
<p>The drug compatibility (physical and chemical), efficacy, and safety of XOPENEX Inhalation Solution when mixed with other drugs in a nebulizer have not been established.
</p>
<p>The safety and efficacy of XOPENEX Inhalation Solution have been established in clinical trials when administered using the PARI LC Jet™ and PARI LC Plus™ nebulizers, and the PARI Master<span class="Sup">®</span> Dura-Neb<span class="Sup">®</span> 2000 and Dura-Neb<span class="Sup">®</span> 3000 compressors. The safety and efficacy of XOPENEX Inhalation Solution when administered using other nebulizer systems have not been established.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Inhalation Solution 3 mL unit-dose, vials in three dosage strengths of levalbuterol; 0.31 mg, 0.63 mg, 1.25 mg. Each strength of XOPENEX Inhalation Solution is available in a shelf carton containing one or more foil pouches, each containing 12 unit-dose vials.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">XOPENEX Inhalation Solution is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levalbuterol or racemic albuterol. Reactions have included <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and oropharyngeal <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> [see <span class="Italics">Warnings and Precautions (<a href="#s11">5.6</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical Bronchospasm</span>
</h2>
<p class="First">XOPENEX Inhalation Solution can produce <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span>, which may be life-threatening. If <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span> occurs, XOPENEX Inhalation Solution should be discontinued immediately and alternative therapy instituted. It should be recognized that <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span>, when associated with inhaled formulations, frequently occurs with the first use of a new vial.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Deterioration of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of XOPENEX Inhalation Solution than usual, this may be a marker of destabilization of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use of Anti-Inflammatory Agents
</h2>
<p class="First">XOPENEX Inhalation Solution is not a substitute for corticosteroids. The use of beta-adrenergic agonist alone may not be adequate to control <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids, to the therapeutic regimen.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Cardiovascular Effects
</h2>
<p class="First">XOPENEX Inhalation Solution, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and symptoms. Although such effects are uncommon after administration of XOPENEX Inhalation Solution at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the t-wave, prolongation of the QTc interval, and <span class="product-label-link" type="condition" conceptid="4095285" conceptname="ST segment depression">ST segment depression</span>. The clinical significance of these findings is unknown. Therefore, XOPENEX Inhalation Solution, like all sympathomimetic amines, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>, especially coronary insufficiency, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Do Not Exceed Recommended Dose
</h2>
<p class="First">Do not exceed the recommended dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The exact cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> is unknown, but <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> following an unexpected development of a severe acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> crisis and subsequent <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> is suspected.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate Hypersensitivity Reactions</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span> may occur after administration of levalbuterol or racemic albuterol. Reactions have included <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and oropharyngeal <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. The potential for <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> must be considered in the clinical evaluation of patients who experience <span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">immediate hypersensitivity reactions</span> while receiving XOPENEX Inhalation Solution.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Coexisting Conditions
</h2>
<p class="First">XOPENEX Inhalation Solution, like all sympathomimetic amines, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorders</span>, especially coronary insufficiency, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>; in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after the use of any beta-adrenergic bronchodilator.
</p>
<p>Changes in blood glucose may occur. Large doses of intravenous racemic albuterol have been reported to aggravate preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus and <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span>
</h2>
<p class="First">As with other beta-adrenergic agonist medications, XOPENEX Inhalation Solution may produce significant <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s14"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<p class="First">The following serious adverse reactions are described below and elsewhere in the labeling:
</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical bronchospasm</span> [<span class="Italics">see Warnings and Precautions (<a href="#s6">5.1</a>)</span>]
</li>
<li>Cardiovascular effects [<span class="Italics">see Warnings and Precautions (<a href="#s9">5.4</a>)</span>]
</li>
<li><span class="product-label-link" type="condition" conceptid="4223759" conceptname="IgE-mediated allergic disorder">Immediate hypersensitivity reactions</span> [<span class="Italics">see Warnings and Precautions (<a href="#s11">5.6</a>)</span>]
</li>
<li><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> [<span class="Italics">see Warnings and Precautions (<a href="#s13">5.8</a>)</span>]
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of the drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Adults and Adolescents 12 Years of Age and Older:</span></p>
<p>Adverse reaction information concerning XOPENEX Inhalation Solution in adults and adolescents is derived from one 4-week, multicenter, randomized, double-blind, active-, and placebo-controlled trial in 362 patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> 12 years of age and older. Adverse reactions reported in ≥2% of patients receiving XOPENEX Inhalation Solution or racemic albuterol and more frequently than in patients receiving placebo are listed in <a href="#t1">Table 1</a>.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1:  Adverse Reactions Reported in a 4-Week, Controlled Clinical Trial in Adults and Adolescents ≥12 Years Old
</span></caption>
<col align="left" width="33.627%">
<col align="left" width="15.123%">
<col align="left" width="17.644%">
<col align="left" width="13.443%">
<col align="left" width="20.164%">
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">a</span> One treatment group, racemic albuterol 1.25 mg, with 68 subjects is omitted.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="4" valign="top">Percent of Patients<span class="Sup">a</span>
</td>
</tr>
<tr>
<td class="Botrule" align="center" rowspan="3" valign="bottom">Placebo<br>(n=75)
</td>
<td class="Botrule" align="center" rowspan="3" valign="bottom">XOPENEX<br>1.25 mg<br>(n=73)
</td>
<td class="Botrule" align="center" rowspan="3" valign="bottom">XOPENEX<br>0.63 mg<br>(n=72)
</td>
<td class="Botrule" align="center" rowspan="3" valign="bottom">Racemic albuterol<br>2.5 mg<br>(n=74)
</td>
</tr>
<tr><td align="left" valign="bottom">Body System
</td></tr>
<tr><td class="Botrule" align="left" valign="top">     Preferred Term
</td></tr>
<tr>
<td align="left" valign="top">Body as a Whole<br>     <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>
</td>
<td align="center" valign="bottom">1.3
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">1.4
</td>
<td align="center" valign="top">4.2
</td>
<td align="center" valign="top">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2.7
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td align="center" valign="top">1.3
</td>
<td align="center" valign="top">1.4
</td>
<td align="center" valign="top">2.8
</td>
<td align="center" valign="top">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Cardiovascular System<br>     <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">2.7
</td>
<td align="center" valign="bottom">2.8
</td>
<td align="center" valign="bottom">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2.7
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Digestive System<br>     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>
</td>
<td align="center" valign="bottom">1.3
</td>
<td align="center" valign="bottom">2.7
</td>
<td align="center" valign="bottom">1.4
</td>
<td align="center" valign="bottom">1.4
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Musculoskeletal System<br>     <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg cramps</span>
</td>
<td align="center" valign="bottom">1.3
</td>
<td align="center" valign="bottom">2.7
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">1.4
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="top">Central Nervous System<br>     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td align="center" valign="bottom">1.3
</td>
<td align="center" valign="bottom">2.7
</td>
<td align="center" valign="bottom">1.4
</td>
<td align="center" valign="bottom">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">9.6
</td>
<td align="center" valign="top">2.8
</td>
<td align="center" valign="top">8.1
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">6.8
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2.7
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Respiratory System<br>     <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span>
</td>
<td align="center" valign="bottom">2.7
</td>
<td align="center" valign="bottom">4.1
</td>
<td align="center" valign="bottom">1.4
</td>
<td align="center" valign="bottom">2.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection viral</span>
</td>
<td align="center" valign="top">9.3
</td>
<td align="center" valign="top">12.3
</td>
<td align="center" valign="top">6.9
</td>
<td align="center" valign="top">12.2
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>
</td>
<td align="center" valign="top">2.7
</td>
<td align="center" valign="top">2.7
</td>
<td align="center" valign="top">11.1
</td>
<td align="center" valign="top">6.8
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span>
</td>
<td align="center" valign="top">2.7
</td>
<td align="center" valign="top">1.4
</td>
<td align="center" valign="top">4.2
</td>
<td align="center" valign="top">2.7
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">     Turbinate <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>
</td>
<td class="Botrule" align="center" valign="top">0
</td>
<td class="Botrule" align="center" valign="top">1.4
</td>
<td class="Botrule" align="center" valign="top">2.8
</td>
<td class="Botrule" align="center" valign="top">0
</td>
</tr>
</tbody>
</table>
<p>The incidence of certain systemic beta-adrenergic adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>) was slightly less in the XOPENEX Inhalation Solution 0.63 mg group compared with the other active treatment groups. The clinical significance of these small differences is unknown.
</p>
<p>Changes in heart rate 15 minutes after drug administration and in plasma glucose and potassium 1 hour after drug administration on day 1 and day 29 were clinically comparable in the XOPENEX Inhalation Solution 1.25 mg and racemic albuterol 2.5 mg groups (see <a href="#t2">Table 2</a>). Changes in heart rate and plasma glucose were slightly less in the XOPENEX Inhalation Solution 0.63 mg group compared with the other active treatment groups (see <a href="#t2">Table 2</a>). The clinical significance of these small differences is unknown. After 4 weeks, effects on heart rate, plasma glucose, and plasma potassium were generally diminished compared with day 1 in all active treatment groups.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Mean Changes from Baseline Heart Rate at 15 Minutes and Glucose and Potassium at 1 Hour after First Dose (Day 1) in Adults and Adolescents ≥12 Years Old
</span></caption>
<col align="left" width="39.990%">
<col align="left" width="19.170%">
<col align="left" width="16.671%">
<col align="left" width="24.169%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="3" valign="top">Mean Changes (day 1)
</td>
</tr>
<tr>
<td align="center" valign="top">Heart Rate
</td>
<td align="center" valign="top">Glucose
</td>
<td align="center" valign="top">Potassium
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Treatment
</td>
<td class="Botrule" align="center" valign="top">(bpm)
</td>
<td class="Botrule" align="center" valign="top">(mg/dL)
</td>
<td class="Botrule" align="center" valign="top">(mEq/L)
</td>
</tr>
<tr>
<td align="left" valign="top">XOPENEX 0.63 mg, n=72
</td>
<td align="center" valign="top">2.4
</td>
<td align="center" valign="top">4.6
</td>
<td align="center" valign="top">-0.2
</td>
</tr>
<tr>
<td align="left" valign="top">XOPENEX 1.25 mg, n=73
</td>
<td align="center" valign="top">6.9
</td>
<td align="center" valign="top">10.3
</td>
<td align="center" valign="top">-0.3
</td>
</tr>
<tr>
<td align="left" valign="top">Racemic albuterol 2.5 mg, n=74
</td>
<td align="center" valign="top">5.7
</td>
<td align="center" valign="top">8.2
</td>
<td align="center" valign="top">-0.3
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Placebo, n=75
</td>
<td class="Botrule" align="center" valign="top">-2.8
</td>
<td class="Botrule" align="center" valign="top">-0.2
</td>
<td class="Botrule" align="center" valign="top">-0.2
</td>
</tr>
</tbody>
</table>
<p>No other clinically relevant laboratory abnormalities related to administration of XOPENEX Inhalation Solution were observed in this study.
</p>
<p>In the clinical trials, a slightly greater number of serious adverse events, discontinuations due to adverse events, and clinically significant ECG changes were reported in patients who received XOPENEX 1.25 mg compared with the other active treatment groups.
</p>
<p>The following adverse reactions, considered potentially related to XOPENEX, occurred in less than 2% of the 292 subjects who received XOPENEX and more frequently than in patients who received placebo in any clinical trial:
</p>
<table width="100%">
<col align="left" width="44.750%">
<col align="left" width="55.250%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">Body as a Whole:
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Cardiovascular System:
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">ECG abnormal</span>, ECG change, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Digestive System:
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">dry throat</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Hemic and Lymphatic System:
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Musculoskeletal System:
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>
</td>
</tr>
<tr>
<td align="left" valign="top">Nervous System:
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span> of the hand, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Special Senses:
</td>
<td align="left" valign="top">eye <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span>
</td>
</tr>
</tbody>
</table>
<p>The following reactions, considered potentially related to XOPENEX, occurred in less than 2% of the treated subjects but at a frequency less than in patients who received placebo: <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbation, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Pediatric Patients 6 to 11 Years of Age:</span></p>
<p>Adverse reaction information concerning XOPENEX Inhalation Solution in pediatric patients is derived from one 3-week, multicenter, randomized, double-blind, active-, and placebo-controlled trial in 316 pediatric patients 6 to 11 years of age. Adverse reactions reported in ≥2% of patients in any treatment group and more frequently than in patients receiving placebo are listed in <a href="#t3">Table 3</a>.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3:  Most Frequently Reported Adverse Reactions (≥2% in Any Treatment Group) and Those Reported More Frequently Than in Placebo during the Double-Blind Period (ITT Population, 6-11 Years Old)
</span></caption>
<col align="left" width="28.812%">
<col align="left" width="13.564%">
<col align="left" width="13.564%">
<col align="left" width="13.564%">
<col align="left" width="14.398%">
<col align="left" width="16.097%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="5" valign="top">Percent of Patients
</td>
</tr>
<tr>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">Racemic
</td>
<td align="center" valign="top">Racemic
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">XOPENEX
</td>
<td align="center" valign="top">XOPENEX
</td>
<td align="center" valign="top">albuterol
</td>
<td align="center" valign="top">albuterol
</td>
</tr>
<tr>
<td align="left" valign="top">Body System
</td>
<td align="center" valign="top">Placebo
</td>
<td align="center" valign="top">0.31 mg
</td>
<td align="center" valign="top">0.63 mg
</td>
<td align="center" valign="top">1.25 mg
</td>
<td align="center" valign="top">2.5 mg
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">     Preferred Term
</td>
<td class="Botrule" align="center" valign="top">(n=59)
</td>
<td class="Botrule" align="center" valign="top">(n=66)
</td>
<td class="Botrule" align="center" valign="top">(n=67)
</td>
<td class="Botrule" align="center" valign="top">(n=64)
</td>
<td class="Botrule" align="center" valign="top">(n=60)
</td>
</tr>
<tr>
<td align="left" valign="top">Body as a Whole<br>     <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
</td>
<td align="center" valign="bottom">3.4
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">1.5
</td>
<td align="center" valign="bottom">3.1
</td>
<td align="center" valign="bottom">6.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>
</td>
<td align="center" valign="top">3.4
</td>
<td align="center" valign="top">6.1
</td>
<td align="center" valign="top">4.5
</td>
<td align="center" valign="top">3.1
</td>
<td align="center" valign="top">5.0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">3.0
</td>
<td align="center" valign="top">3.0
</td>
<td align="center" valign="top">1.6
</td>
<td align="center" valign="top">1.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>
</td>
<td align="center" valign="top">5.1
</td>
<td align="center" valign="top">9.1
</td>
<td align="center" valign="top">3.0
</td>
<td align="center" valign="top">1.6
</td>
<td align="center" valign="top">6.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td align="center" valign="top">8.5
</td>
<td align="center" valign="top">7.6
</td>
<td align="center" valign="top">11.9
</td>
<td align="center" valign="top">9.4
</td>
<td align="center" valign="top">3.3
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>
</td>
<td align="center" valign="top">3.4
</td>
<td align="center" valign="top">3.0
</td>
<td align="center" valign="top">1.5
</td>
<td align="center" valign="top">4.7
</td>
<td align="center" valign="top">6.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infection</span>
</td>
<td align="center" valign="top">5.1
</td>
<td align="center" valign="top">7.6
</td>
<td align="center" valign="top">9.0
</td>
<td align="center" valign="top">4.7
</td>
<td align="center" valign="top">8.3
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Digestive System<br>     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">1.5
</td>
<td align="center" valign="bottom">6.0
</td>
<td align="center" valign="bottom">1.6
</td>
<td align="center" valign="bottom">0
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="top">Hemic and Lymphatic<br>     <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span>
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">3.0
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">1.6
</td>
<td align="center" valign="bottom">0
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="top">Musculoskeletal System<br>     <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">1.5
</td>
<td align="center" valign="bottom">1.6
</td>
<td align="center" valign="bottom">3.3
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
<td align="center" valign="bottom"></td>
</tr>
<tr>
<td align="left" valign="top">Respiratory System<br>     <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</td>
<td align="center" valign="bottom">5.1
</td>
<td align="center" valign="bottom">9.1
</td>
<td align="center" valign="bottom">9.0
</td>
<td align="center" valign="bottom">6.3
</td>
<td align="center" valign="bottom">10.0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</td>
<td align="center" valign="top">6.8
</td>
<td align="center" valign="top">3.0
</td>
<td align="center" valign="top">10.4
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">6.7
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span>
</td>
<td align="center" valign="top">1.7
</td>
<td align="center" valign="top">6.1
</td>
<td align="center" valign="top">10.4
</td>
<td align="center" valign="top">3.1
</td>
<td align="center" valign="top">5.0
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Skin and Appendages<br>     <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span>
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">0
</td>
<td align="center" valign="bottom">3.3
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">7.5
</td>
<td align="center" valign="top">1.6
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">3.0
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">0
</td>
</tr>
<tr>
<td align="left" valign="top">     
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Special Senses<br>     <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span>
</td>
<td class="Botrule" align="center" valign="bottom">1.7
</td>
<td class="Botrule" align="center" valign="bottom">0
</td>
<td class="Botrule" align="center" valign="bottom">0
</td>
<td class="Botrule" align="center" valign="bottom">0
</td>
<td class="Botrule" align="center" valign="bottom">3.3
</td>
</tr>
</tbody>
</table>
<p>Note: Subjects may have more than one adverse event per body system and preferred term.
</p>
<p>Changes in heart rate, plasma glucose, and serum potassium are shown in <a href="#t4a">Table 4</a>. The clinical significance of these small differences is unknown.
</p>
<a name="t4a"></a><table width="100%">
<caption><span>Table 4:  Mean Changes from Baseline Heart Rate at 30 Minutes and Glucose and Potassium at 1 Hour after First Dose (Day 1) and Last Dose (Day 21) in Children 6-11 Years Old
</span></caption>
<col align="left" width="33.900%">
<col align="left" width="17.800%">
<col align="left" width="22.025%">
<col align="left" width="26.275%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="3" valign="top">Mean Changes (Day 1)
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">Heart Rate
</td>
<td align="center" valign="top">Glucose
</td>
<td align="center" valign="top">Potassium
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Treatment
</td>
<td class="Botrule" align="center" valign="top">(bpm)
</td>
<td class="Botrule" align="center" valign="top">(mg/dL)
</td>
<td class="Botrule" align="center" valign="top">(mEq/L)
</td>
</tr>
<tr>
<td align="left" valign="top">XOPENEX 0.31 mg, n=66
</td>
<td align="center" valign="top">0.8
</td>
<td align="center" valign="top">4.9
</td>
<td align="center" valign="top">-0.31
</td>
</tr>
<tr>
<td align="left" valign="top">XOPENEX 0.63 mg, n=67
</td>
<td align="center" valign="top">6.7
</td>
<td align="center" valign="top">5.2
</td>
<td align="center" valign="top">-0.36
</td>
</tr>
<tr>
<td align="left" valign="top">Racemic albuterol 1.25 mg, n=64
</td>
<td align="center" valign="top">6.4
</td>
<td align="center" valign="top">8.0
</td>
<td align="center" valign="top">-0.27
</td>
</tr>
<tr>
<td align="left" valign="top">Racemic albuterol 2.5 mg, n=60
</td>
<td align="center" valign="top">10.9
</td>
<td align="center" valign="top">10.8
</td>
<td align="center" valign="top">-0.56
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Placebo, n=59
</td>
<td class="Botrule" align="center" valign="top">-1.8
</td>
<td class="Botrule" align="center" valign="top">0.6
</td>
<td class="Botrule" align="center" valign="top">-0.05
</td>
</tr>
</tbody>
</table>
<a name="t4b"></a><table width="100%">
<caption><span>Table 4:  Mean Changes from Baseline Heart Rate at 30 Minutes and Glucose and Potassium at 1 Hour after First Dose (Day 1) and Last Dose (Day 21) in Children 6-11 Years Old (continued)
</span></caption>
<col align="left" width="33.900%">
<col align="left" width="20.350%">
<col align="left" width="22.875%">
<col align="left" width="22.875%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="3" valign="top">Mean Changes (Day 21)
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">Heart Rate
</td>
<td align="center" valign="top">Glucose
</td>
<td align="center" valign="top">Potassium
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Treatment
</td>
<td class="Botrule" align="center" valign="top">(bpm)
</td>
<td class="Botrule" align="center" valign="top">(mg/dL)
</td>
<td class="Botrule" align="center" valign="top">(mEq/L)
</td>
</tr>
<tr>
<td align="left" valign="top">XOPENEX 0.31 mg, n=60
</td>
<td align="center" valign="top">0
</td>
<td align="center" valign="top">2.6
</td>
<td align="center" valign="top">-0.32
</td>
</tr>
<tr>
<td align="left" valign="top">XOPENEX 0.63 mg, n=66
</td>
<td align="center" valign="top">3.8
</td>
<td align="center" valign="top">5.8
</td>
<td align="center" valign="top">-0.34
</td>
</tr>
<tr>
<td align="left" valign="top">Racemic albuterol 1.25 mg, n=62
</td>
<td align="center" valign="top">5.8
</td>
<td align="center" valign="top">1.7
</td>
<td align="center" valign="top">-0.18
</td>
</tr>
<tr>
<td align="left" valign="top">Racemic albuterol 2.5 mg, n=54
</td>
<td align="center" valign="top">5.7
</td>
<td align="center" valign="top">11.8
</td>
<td align="center" valign="top">-0.26
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Placebo, n=55
</td>
<td class="Botrule" align="center" valign="top">-1.7
</td>
<td class="Botrule" align="center" valign="top">1.1
</td>
<td class="Botrule" align="center" valign="top">-0.04
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience
</h2>
<p class="First">In addition to the adverse reactions reported in clinical trials, the following adverse reactions have been observed in postapproval use of XOPENEX Inhalation Solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to their seriousness, their frequency of reporting, or their likely beta-mediated mechanism: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> (including <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">extrasystoles</span>), <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastrooesophageal reflux disease</span> (<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">GERD</span>), <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.
</p>
<p>In addition, XOPENEX Inhalation Solution, like other sympathomimetic agents, can cause adverse reactions such as <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, angina, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, central nervous system stimulation, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">sleeplessness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and drying or irritation of the oropharynx.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s19"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Short-Acting Bronchodilators
</h2>
<p class="First">Avoid concomitant use of other short-acting sympathomimetic bronchodilators or epinephrine in patients being treated with XOPENEX Inhalation Solution. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Beta-blockers
</h2>
<p class="First">Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-adrenergic agonists such as XOPENEX Inhalation Solution, but may produce severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients. Therefore, patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> should not normally be treated with beta-blockers. However, under certain circumstances, e.g., prophylaxis after <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Diuretics
</h2>
<p class="First">The ECG changes or <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with non-potassium-sparing diuretics. Consider monitoring potassium levels.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Digoxin
</h2>
<p class="First">Mean decreases of 16% and 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of racemic albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving XOPENEX Inhalation Solution and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and XOPENEX Inhalation Solution.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Monoamine Oxidase Inhibitors or Tricyclic Antidepressants
</h2>
<p class="First">XOPENEX Inhalation Solution should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of levalbuterol on the vascular system may be potentiated. Consider alternative therapy in patients taking MAO inhibitors or tricyclic antidepressants.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s25"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s26"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s27"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic Effects: Pregnancy Category C.</span></p>
<p>There are no adequate and well-controlled studies of XOPENEX Inhalation Solution in pregnant women. Because animal reproduction studies are not always predictive of human response, XOPENEX Inhalation Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<p>During worldwide marketing experience, various congenital anomalies, including <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb defects</span>, have been reported in newborns of women treated with racemic albuterol which contains the levalbuterol isomer (active drug substance of XOPENEX Inhalation Solution). However, since multiple medications were taken during some of the pregnancies and there was no consistent pattern of anomalies, it was not possible to establish a relationship between racemic albuterol use and the occurrence of these congenital anomalies.
</p>
<p>In animal studies, oral administration of levalbuterol HCl to pregnant New Zealand White rabbits found no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> at doses up to 25 mg/kg/day (approximately 108 times the maximum recommended daily inhalation [MRDI] dose of levalbuterol HCl for adults on a mg/m<span class="Sup">2</span> basis).
</p>
<p>However, other studies demonstrated that racemic albuterol sulfate was teratogenic in mice and rabbits at doses comparable to the human therapeutic range. Pregnant mice administered racemic albuterol sulfate subcutaneously had a dose-related increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in their fetuses (4.5% of fetuses at 0.25 mg/kg/day or greater, corresponding to approximately 0.3 times the MRDI dose, 9.3% of fetuses at 2.5 mg/kg/day, approximately 3 times the MRDI dose of levalbuterol HCl for adults on a mg/m<span class="Sup">2</span> basis). The drug did not induce <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> formation when administered subcutaneously at a dose of 0.025 mg/ kg/day (approximately 0.03 times the MRDI dose of levalbuterol HCl for adults on a mg/m<span class="Sup">2</span> basis). In addition, oral administration of racemic albuterol sulfate to pregnant rabbits resulted in an increased incidence of cranioschisis in fetuses (approximately 215 times the MRDI dose of levalbuterol HCl for adults on a mg/m<span class="Sup">2</span> basis).
</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s28"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold">Non-Teratogenic Effects:</span> A study in which pregnant rats were dosed with radiolabeled racemic albuterol sulfate demonstrated that drug-related material is transferred from the maternal circulation to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s29"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery
</h2>
<p class="First">Because of the potential for beta-adrenergic agonists to interfere with uterine contractility, the use of XOPENEX Inhalation Solution for the treatment of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.
</p>
<p>XOPENEX Inhalation Solution has not been approved for the management of preterm labor. The benefit:risk ratio when levalbuterol HCl is administered for tocolysis has not been established. Serious adverse reactions, including maternal <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, have been reported during or following treatment of <span class="product-label-link" type="condition" conceptid="4273560" conceptname="Premature labor">premature labor</span> with beta<span class="Sub">2</span>-agonists, including racemic albuterol.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s30"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Plasma concentrations of levalbuterol after inhalation of therapeutic doses are very low in humans. It is not known whether levalbuterol is excreted in human milk.
</p>
<p>Because of the potential for tumorigenicity shown for racemic albuterol in animal studies and the lack of experience with the use of XOPENEX Inhalation Solution by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Caution should be exercised when XOPENEX Inhalation Solution is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s31"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients 6 Years of Age and Older</span></p>
<p>The safety and efficacy of XOPENEX Inhalation Solution have been established in pediatric patients 6 years of age and older in an adequate and well-controlled clinical trial [see <span class="Italics">Adverse Reactions (<a href="#s14">6</a>) and Clinical Studies (<a href="#s51">14</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-8.4.2"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatric Patients less than 6 Years of Age</span></p>
<p>XOPENEX Inhalation Solution is not indicated for pediatric patients less than 6 years of age.
</p>
<p>Clinical trials with XOPENEX Inhalation Solution in this age group failed to meet the primary efficacy endpoint and demonstrated an increased number of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>-related adverse reactions following chronic XOPENEX treatment.
</p>
<p>XOPENEX Inhalation Solution was studied in 379 pediatric patients less than 6 years of age with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or reactive airway disease - (291 patients 2 to 5 years of age, and 88 patients from birth to less than 2 years of age). Efficacy and safety data for XOPENEX Inhalation Solution in this age group are primarily available from one 3-week, multicenter, randomized, double-blind, active and placebo-controlled study (Study 1) in 211 pediatric patients between the ages of 2 and 5 years, of whom 119 received XOPENEX Inhalation Solution. Over the 3 week treatment period, there were no significant treatment differences in the Pediatric <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> Questionnaire (PAQ) total score between groups receiving XOPENEX Inhalation Solution 0.31 mg, XOPENEX Inhalation Solution 0.63 mg, racemic albuterol, and placebo. Additional safety data following chronic dosing is available from a 4-week, multicenter, randomized, modified-blind, placebo-controlled study (Study 2) of 196 patients between the ages of birth and 3 years, of whom 63 received open-label XOPENEX Inhalation Solution. In these two studies, treatment-emergent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbations or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>-related adverse reactions and treatment discontinuations due to <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> occurred at a higher frequency in XOPENEX Inhalation-treated subjects compared to control (<a href="#t5">Table 5</a>). Other adverse reactions were consistent with those observed in the clinical trial population of patients 6 years of age and older [see Adverse Reactions (<a href="#s15">6.1</a>)].
</p>
<a name="t5"></a><table width="100%">
<caption><span>Table 5:  <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>-related Adverse Reactions in 3- and 4-Week Clinical Trials in Children Birth to &lt;6 Years of Age
</span></caption>
<col align="left" width="30.200%">
<col align="left" width="27.750%">
<col align="left" width="22.700%">
<col align="left" width="19.350%">
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><p class="First Footnote">*<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> exacerbation defined as worsening of <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms or pulmonary function that required any of the following: emergency department visit, hospitalization, therapeutic intervention with oral or parenteral steroids, unscheduled clinic visit to treat acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms
</p></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><p class="First Footnote">**Includes the following Preferred Terms (whether considered by the investigator to be related or unrelated to drug): <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, status asthmaticus, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span><br>Exacerbations*<br>n (%)
</td>
<td class="Botrule Toprule" align="left" valign="top">Treatment<br>Discontinuations<br>due to <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span><br>n (%)
</td>
<td class="Botrule Toprule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>-related<br>Adverse Reactions**<br>n (%)
</td>
</tr>
<tr>
<td align="left" valign="top">Study 1<br>XOPENEX 0.31 mg, n=58
</td>
<td align="left" valign="bottom">6 (10)
</td>
<td align="left" valign="bottom">4 (7)
</td>
<td align="left" valign="bottom">—
</td>
</tr>
<tr>
<td align="left" valign="top">XOPENEX 0.63 mg, n=51
</td>
<td align="left" valign="top">7 (14)
</td>
<td align="left" valign="top">6 (12)
</td>
<td align="left" valign="top">—
</td>
</tr>
<tr>
<td align="left" valign="top">Racemic albuterol, n=52
</td>
<td align="left" valign="top">3 (6)
</td>
<td align="left" valign="top">2 (4)
</td>
<td align="left" valign="top">—
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Placebo, n=50
</td>
<td class="Botrule" align="left" valign="top">2 (4)
</td>
<td class="Botrule" align="left" valign="top">2 (4)
</td>
<td class="Botrule" align="left" valign="top">—
</td>
</tr>
<tr>
<td align="left" valign="top">Study 2<br>XOPENEX 0.31 mg, n=63
</td>
<td align="left" valign="bottom">—
</td>
<td align="left" valign="bottom">2 (3)
</td>
<td align="left" valign="bottom">6 (10)
</td>
</tr>
<tr>
<td align="left" valign="top">Levalbuterol HFA inhalation aerosol, n=65
</td>
<td align="left" valign="middle">—
</td>
<td align="left" valign="middle">1 (2)
</td>
<td align="left" valign="middle">8 (12)
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Placebo, n=68
</td>
<td class="Botrule" align="left" valign="top">—
</td>
<td class="Botrule" align="left" valign="top">0
</td>
<td class="Botrule" align="left" valign="top">3 (4)
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s34"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">Clinical studies of XOPENEX Inhalation Solution did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Only 5 patients 65 years of age and older were treated with XOPENEX Inhalation Solution in a 4-week clinical study [see <span class="Italics">Clinical Pharmacology (<a href="#s38">12</a>)</span> and <span class="Italics">Clinical Studies (<a href="#s51">14</a>)</span>] (n=2 for 0.63 mg and n=3 for 1.25 mg). In these patients, bronchodilation was observed after the first dose on day 1 and after 4 weeks of treatment. In general, patients 65 years of age and older should be started at a dose of 0.63 mg of XOPENEX Inhalation Solution. If clinically warranted due to insufficient bronchodilator response, the dose of XOPENEX Inhalation Solution may be increased in elderly patients as tolerated, in conjunction with frequent clinical and laboratory monitoring, to the maximum recommended daily dose [see <span class="Italics">Dosage and Administration (<a href="#s2">2</a>)</span>].
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">Albuterol is known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s36"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE
</h1>
<p class="First">The expected symptoms with overdosage are those of excessive beta-adrenergic receptor stimulation and/or occurrence or exaggeration of any of the symptoms listed under <span class="Italics">Adverse Reactions (<a href="#s14">6</a>)</span>, e.g., <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, angina, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> with rates up to 200 beats/min., <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">sleeplessness</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> also may occur. As with all sympathomimetic medications, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may be associated with the abuse of XOPENEX Inhalation Solution. Treatment consists of discontinuation of XOPENEX Inhalation Solution together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. There is insufficient evidence to determine if dialysis is beneficial for overdosage of XOPENEX Inhalation Solution.
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s37"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">XOPENEX Inhalation Solution is a sterile, clear, colorless, preservative-free solution of the hydrochloride salt of levalbuterol, the (R)-enantiomer of the drug substance racemic albuterol. Levalbuterol HCl is a relatively selective beta<span class="Sub">2</span>-adrenergic receptor agonist [see <span class="Italics">Clinical Pharmacology (<a href="#s38">12</a>)</span>]. The chemical name for levalbuterol HCl is (R)-α<span class="Sup">1</span>-[[(1,1-dimethylethyl) amino]methyl]-4-hydroxy-1,3-benzenedimethanol hydrochloride, and its established chemical structure is as follows:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Chemical Structure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-01.jpg">
</div>
<p>The molecular weight of levalbuterol HCl is 275.8, and its empirical formula is C<span class="Sub">13</span>H<span class="Sub">21</span>NO<span class="Sub">3</span>•HCl. It is a white to off-white, crystalline solid, with a melting point of approximately 187°C and solubility of approximately 180 mg/mL in water.
</p>
<p>Levalbuterol HCl is the USAN modified name for (R)-albuterol HCl in the United States.
</p>
<p>XOPENEX Inhalation Solution is supplied in unit-dose vials and requires no dilution before administration by nebulization. Each 3 mL unit-dose vial contains 0.31 mg of levalbuterol (as 0.36 mg of levalbuterol HCl) or 0.63 mg of levalbuterol (as 0.73 mg of levalbuterol HCl) or 1.25 mg of levalbuterol (as 1.44 mg of levalbuterol HCl), sodium chloride to adjust tonicity, and sulfuric acid to adjust the pH to 4.0 (3.3 to 4.5).
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s38"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s39"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action
</h2>
<p class="First">Activation of beta<span class="Sub">2</span>-adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3′, 5′ adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn inhibits the phosphorylation of myosin and lowers intracellular ionic calcium concentrations, resulting in <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span>. Levalbuterol relaxes the smooth muscles of all airways, from the trachea to the terminal bronchioles. Increased cyclic AMP concentrations are also associated with the inhibition of release of mediators from mast cells in the airway. Levalbuterol acts as a functional antagonist to relax the airway irrespective of the spasmogen involved, thus protecting against all bronchoconstrictor challenges. While it is recognized that beta<span class="Sub">2</span>-adrenergic receptors are the predominant receptors on bronchial smooth muscle, data indicate that there are beta-receptors in the human heart, 10% to 50% of which are beta<span class="Sub">2</span>-adrenergic receptors. The precise function of these receptors has not been established [see <span class="Italics">Warnings and Precautions (<a href="#s9">5.4</a>)</span>]. However, all beta-adrenergic agonist drugs can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.
</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s40"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Adults and Adolescents ≥12 Years Old</span></p>
<p>In a randomized, double-blind, placebo-controlled, cross-over study, 20 adults with mild-tomoderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> received single doses of XOPENEX Inhalation Solution (0.31 mg, 0.63 mg, and 1.25 mg) and racemic albuterol sulfate inhalation solution (2.5 mg). All doses of active treatment produced a significantly greater degree of bronchodilation (as measured by percent change from pre-dose mean FEV<span class="Sub">1</span>) than placebo, and there were no significant differences between any of the active treatment arms. The bronchodilator responses to 1.25 mg of XOPENEX Inhalation Solution and 2.5 mg of racemic albuterol sulfate inhalation solution were clinically comparable over the 6-hour evaluation period, except for a slightly longer duration of action (&gt;15% increase in FEV<span class="Sub">1</span> from baseline) after administration of 1.25 mg of XOPENEX Inhalation Solution. Systemic beta-adrenergic adverse effects were observed with all active doses and were generally dose-related for (R)-albuterol. XOPENEX Inhalation Solution at a dose of 1.25 mg produced a slightly higher rate of systemic beta-adrenergic adverse effects than the 2.5 mg dose of racemic albuterol sulfate inhalation solution.
</p>
<p>In a randomized, double-blind, placebo-controlled, cross-over study, 12 adults with mildto-moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> were challenged with inhaled methacholine chloride 20 and 180 minutes following administration of a single dose of 2.5 mg of racemic albuterol sulfate, 1.25 mg of XOPENEX, 1.25 mg of (S)-albuterol, or placebo using a Pari LC Jet™ nebulizer. Racemic albuterol sulfate, XOPENEX, and (S)-albuterol had a protective effect against methacholine-induced <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchoconstriction</span> 20 minutes after administration, although the effect of (S)-albuterol was minimal. At 180 minutes after administration, the bronchoprotective effect of 1.25 mg of XOPENEX was comparable to that of 2.5 mg of racemic albuterol sulfate. At 180 minutes after administration, 1.25 mg of (S)-albuterol had no bronchoprotective effect.
</p>
<p>In a clinical study in adults with mild-to-moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, comparable efficacy (as measured by change from baseline FEV<span class="Sub">1</span>) and safety (as measured by heart rate, blood pressure, ECG, serum potassium, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>) were demonstrated after a cumulative dose of 5 mg of XOPENEX Inhalation Solution (four consecutive doses of 1.25 mg administered every 30 minutes) and 10 mg of racemic albuterol sulfate inhalation solution (four consecutive doses of 2.5 mg administered every 30 minutes).
</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s42"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Adults and Adolescents ≥12 Years Old</span></p>
<p>The inhalation pharmacokinetics of XOPENEX Inhalation Solution were investigated in a randomized cross-over study in 30 healthy adults following administration of a single dose of 1.25 mg and a cumulative dose of 5 mg of XOPENEX Inhalation Solution and a single dose of 2.5 mg and a cumulative dose of 10 mg of racemic albuterol sulfate inhalation solution by nebulization using a PARI LC Jet™ nebulizer with a Dura-Neb<span class="Sup">®</span> 2000 compressor.
</p>
<p>Following administration of a single 1.25 mg dose of XOPENEX Inhalation Solution, exposure to (R)-albuterol (AUC of 3.3 ng•hr/mL) was approximately 2-fold higher than following administration of a single 2.5 mg dose of racemic albuterol inhalation solution (AUC of 1.7 ng•hr/mL) (see <a href="#t5">Table 5</a>). Following administration of a cumulative 5 mg dose of XOPENEX Inhalation Solution (1.25 mg given every 30 minutes for a total of four doses) or a cumulative 10 mg dose of racemic albuterol inhalation solution (2.5 mg given every 30 minutes for a total of four doses), C<span class="Sub">max</span> and AUC of (R)-albuterol were comparable (see <a href="#t6">Table 6</a>).
</p>
<a name="t6"></a><table width="100%">
<caption><span>Table 6:  Mean (SD) Values for Pharmacokinetic Parameters in Healthy Adults
</span></caption>
<col align="left" width="27.120%">
<col align="left" width="13.560%">
<col align="left" width="17.800%">
<col align="left" width="17.800%">
<col align="left" width="23.720%">
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote"><span class="Sup">γ</span> Median (Min, Max) reported for T<span class="Sub">max</span>.
</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote">* A negative T<span class="Sub">max</span> indicates C<span class="Sub">max</span> occurred between first and last nebulizations.
</p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">** Values reflect only (R)-albuterol and do not include (S)-albuterol.
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="2" valign="middle">Single Dose
</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="middle">Cumulative Dose
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top">Racemic
</td>
<td align="center" valign="middle"></td>
<td align="center" valign="top">Racemic
</td>
</tr>
<tr>
<td align="left" valign="middle"></td>
<td align="center" valign="top">XOPENEX
</td>
<td align="center" valign="top">albuterol
</td>
<td align="center" valign="top">XOPENEX
</td>
<td align="center" valign="top">albuterol
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle"></td>
<td class="Botrule" align="center" valign="top">1.25 mg
</td>
<td class="Botrule" align="center" valign="top">sulfate 2.5 mg
</td>
<td class="Botrule" align="center" valign="top">5 mg
</td>
<td class="Botrule" align="center" valign="top">sulfate 10 mg
</td>
</tr>
<tr>
<td align="left" valign="top">C<span class="Sub">max</span> (ng/mL)<br>      (R)-albuterol
</td>
<td align="center" valign="bottom">1.1 (0.45)
</td>
<td align="center" valign="bottom">0.8 (0.41)**
</td>
<td align="center" valign="bottom">4.5 (2.20)
</td>
<td align="center" valign="bottom">4.2 (1.51)**
</td>
</tr>
<tr>
<td align="left" valign="top">Tmax (h)γ<br>      (R)-albuterol
</td>
<td align="center" valign="bottom">0.2
</td>
<td align="center" valign="bottom">0.2
</td>
<td align="center" valign="bottom">0.2
</td>
<td align="center" valign="bottom">0.2
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">(0.17, 0.37)
</td>
<td align="center" valign="top">(0.17, 1.50)
</td>
<td align="center" valign="top">(–0.18*, 1.25)
</td>
<td align="center" valign="top">(–0.28*, 1.00)
</td>
</tr>
<tr>
<td align="left" valign="top">AUC (ng•hr/mL)<br>      (R)-albuterol
</td>
<td align="center" valign="bottom">3.3 (1.58)
</td>
<td align="center" valign="bottom">1.7 (0.99)**
</td>
<td align="center" valign="bottom">17.4 (8.56)
</td>
<td align="center" valign="bottom">16.0 (7.12)**
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">T<span class="Sub">½</span> (h)<br>      (R)-albuterol
</td>
<td class="Botrule" align="center" valign="bottom">3.3 (2.48)
</td>
<td class="Botrule" align="center" valign="bottom">1.5 (0.61)
</td>
<td class="Botrule" align="center" valign="bottom">4.0 (1.05)
</td>
<td class="Botrule" align="center" valign="bottom">4.1 (0.97)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Children 6-11 Years Old</span></p>
<p>The pharmacokinetic parameters of (R)- and (S)-albuterol in children with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> were obtained using population pharmacokinetic analysis. These data are presented in <a href="#t7">Table 7</a>. For comparison, adult data obtained by conventional pharmacokinetic analysis from a different study also are presented in <a href="#t7">Table 7</a>.
</p>
<p>In children, AUC and C<span class="Sub">max</span> of (R)-albuterol following administration of 0.63 mg XOPENEX Inhalation Solution were comparable to those following administration of 1.25 mg racemic albuterol sulfate inhalation solution.
</p>
<p>When the same dose of 0.63 mg of XOPENEX Inhalation Solution was given to children and adults, the predicted C<span class="Sub">max</span> of (R)-albuterol in children was similar to that in adults (0.52 vs. 0.56 ng/mL), while predicted AUC in children (2.55 ng•hr/mL) was about 1.5-fold higher than that in adults (1.65 ng•hr/mL). These data support lower doses for children 6-11 years old compared with the adult doses [see <span class="Italics">Dosage and Administration (<a href="#s2">2</a>)</span>].
</p>
<a name="t7"></a><table width="100%">
<caption><span>Table 7:  (R)-Albuterol Exposure in Adults and Pediatric Subjects (6-11 years)
</span></caption>
<col align="left" width="19.129%">
<col align="left" width="13.043%">
<col align="left" width="12.171%">
<col align="left" width="13.914%">
<col align="left" width="13.914%">
<col align="left" width="13.914%">
<col align="left" width="13.914%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">a</span> The values are predicted by assuming linear pharmacokinetics
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">b</span> The data obtained from <a href="#t6">Table 6</a></p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">c</span> Area under the plasma concentration curve from time 0 to infinity
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">d</span> Maximum plasma concentration
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="left" valign="top"></td>
<td class="Botrule Toprule" align="center" colspan="4" valign="top">Children 6-11 years
</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top">Adults ≥12 years
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="middle"></td>
<td align="center" valign="top">Racemic
</td>
<td align="center" valign="top">Racemic
</td>
<td align="center" valign="middle"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">XOPENEX
</td>
<td align="center" valign="top">XOPENEX
</td>
<td align="center" valign="top">albuterol
</td>
<td align="center" valign="top">albuterol
</td>
<td align="center" valign="top">XOPENEX
</td>
<td align="center" valign="top">XOPENEX
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">Treatment
</td>
<td class="Botrule" align="center" valign="top">0.31 mg
</td>
<td class="Botrule" align="center" valign="top">0.63 mg
</td>
<td class="Botrule" align="center" valign="top">1.25 mg
</td>
<td class="Botrule" align="center" valign="top">2.5 mg
</td>
<td class="Botrule" align="center" valign="top">0.63 mg
</td>
<td class="Botrule" align="center" valign="top">1.25 mg
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top">AUC0-∞<br>(ng•hr/mL) <span class="Sup">c</span>
</td>
<td class="Botrule" align="center" valign="bottom">1.36
</td>
<td class="Botrule" align="center" valign="bottom">2.55
</td>
<td class="Botrule" align="center" valign="bottom">2.65
</td>
<td class="Botrule" align="center" valign="bottom">5.02
</td>
<td class="Botrule" align="center" valign="bottom">1.65 <span class="Sup">a</span>
</td>
<td class="Botrule" align="center" valign="bottom">3.3 <span class="Sup">b</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Cmax<br>(ng/mL) <span class="Sup">d</span>
</td>
<td class="Botrule" align="center" valign="bottom">0.303
</td>
<td class="Botrule" align="center" valign="bottom">0.521
</td>
<td class="Botrule" align="center" valign="bottom">0.553
</td>
<td class="Botrule" align="center" valign="bottom">1.08
</td>
<td class="Botrule" align="center" valign="bottom">0.56 <span class="Sup">a</span>
</td>
<td class="Botrule" align="center" valign="bottom">1.1 <span class="Sup">b</span>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism and Elimination</span></p>
<p>Information available in the published literature suggests that the primary enzyme responsible for the metabolism of albuterol enantiomers in humans is SULT1A3 (sulfotransferase). When racemic albuterol was administered either intravenously or via inhalation after oral charcoal administration, there was a 3- to 4-fold difference in the area under the concentration-time curves between the (R)- and (S)-albuterol enantiomers, with (S)-albuterol concentrations being consistently higher. However, without charcoal pretreatment, after either oral or inhalation administration the differences were 8- to 24-fold, suggesting that (R)-albuterol is preferentially metabolized in the gastrointestinal tract, presumably by SULT1A3.
</p>
<p>The primary route of elimination of albuterol enantiomers is through renal excretion (80% to 100%) of either the parent compound or the primary metabolite. Less than 20% of the drug is detected in the feces. Following intravenous administration of racemic albuterol, between 25% and 46% of the (R)-albuterol fraction of the dose was excreted as unchanged (R)-albuterol in the urine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.3.4.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of XOPENEX Inhalation Solution has not been evaluated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-11.3.4.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on the pharmacokinetics of racemic albuterol was evaluated in 5 subjects with creatinine clearance of 7 to 53 mL/min, and the results were compared with those from healthy volunteers. <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal disease</span> had no effect on the half-life, but there was a 67% decline in racemic albuterol clearance. Caution should be used when administering high doses of XOPENEX Inhalation Solution to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics">Use in Specific Populations (<a href="#s35">8.6</a>)</span>].
</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s49"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s50"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Although there have been no carcinogenesis studies with levalbuterol HCl, racemic albuterol sulfate has been evaluated for its carcinogenic potential.
</p>
<p>In a 2-year study in Sprague-Dawley rats, dietary administration of racemic albuterol sulfate resulted in a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at doses of 2 mg/kg/day and greater (approximately 4 times the MRDI dose of levalbuterol HCl for adults and approximately 5 times the MRDI dose of levalbuterol HCl for children on a mg/m<span class="Sup">2</span> basis). In an 18-month study in CD-1 mice and a 22-month study in the golden hamster, dietary  administration of racemic albuterol sulfate showed no evidence of tumorigenicity. Dietary doses in CD-1 mice were up to 500 mg/kg/day (approximately 540 times the MRDI dose of levalbuterol HCl for adults and approximately 630 times the MRDI dose of levalbuterol HCl for children on a mg/m<span class="Sup">2</span> basis) and doses in the golden hamster study were up to 50 mg/kg/day (approximately 90 times the MRDI dose of levalbuterol HCl for adults on a mg/m<span class="Sup">2</span> basis and approximately 105 times the MRDI dose of levalbuterol HCl for children on a mg/m<span class="Sup">2</span> basis).
</p>
<p>Levalbuterol HCl was not mutagenic in the Ames test or the CHO/HPRT Mammalian Forward Gene Mutation Assay. Levalbuterol HCl was not clastogenic in the <span class="Italics">in vivo</span> micronucleus test in mouse bone marrow. Racemic albuterol sulfate was not clastogenic in an <span class="Italics">in vitro</span> chromosomal aberration assay in CHO cell cultures.
</p>
<p>No fertility studies have been conducted with levalbuterol hydrochloride. Reproduction studies in rats using racemic albuterol sulfate demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg/day (approximately 108 times the maximum recommended daily inhalation dose of levalbuterol HCl for adults on a mg/m<span class="Sup">2</span> basis).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s51"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Adults and Adolescents ≥12 Years Old</span></p>
<p>The safety and efficacy of XOPENEX Inhalation Solution were evaluated in a 4-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study in 362 adult and adolescent patients 12 years of age and older, with mild-to-moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (mean baseline FEV<span class="Sub">1</span> 60% of predicted). Approximately half of the patients were also receiving inhaled corticosteroids. Patients were randomized to receive XOPENEX 0.63 mg, XOPENEX 1.25 mg, racemic albuterol sulfate 1.25 mg, racemic albuterol sulfate 2.5 mg, or placebo three times a day administered via a PARI LC Plus™ nebulizer and a Dura-Neb<span class="Sup">®</span> portable compressor. Racemic albuterol delivered by a chlorofluorocarbon (CFC) metered-dose inhaler (MDI) was used on an as-needed basis as the rescue medication.
</p>
<p>Efficacy, as measured by the mean percent change from baseline FEV<span class="Sub">1</span>, was demonstrated for all active treatment regimens compared with placebo on day 1 and day 29. On both day 1 (see <a href="#fig1">Figure 1</a>) and day 29 (see <a href="#fig2">Figure 2</a>), 1.25 mg of XOPENEX demonstrated the largest mean percent change from baseline FEV<span class="Sub">1</span> compared with the other active treatments. A dose of 0.63 mg of XOPENEX and 2.5 mg of racemic albuterol sulfate produced a clinically comparable mean percent change from baseline FEV<span class="Sub">1</span> on both day 1 and day 29.
</p>
<p><a name="fig1"></a><span class="Bold">Figure 1:  Mean Percent Change from Baseline FEV</span><span class="Bold"><span class="Sub">1
</span></span><span class="Bold">on Day 1, Adults and Adolescents ≥12 years old</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-02.jpg">
</div>
<p><a name="fig2"></a><span class="Bold">Figure 2:  Mean Percent Change from Baseline FEV</span><span class="Bold"><span class="Sub">1
</span></span><span class="Bold">on Day 29, Adults and Adolescents ≥12 years old</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Figure 2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-03.jpg">
</div>
<p>The mean time to onset of a 15% increase in FEV<span class="Sub">1</span> over baseline for levalbuterol at doses of 0.63 mg and 1.25 mg was approximately 17 minutes and 10 minutes, respectively, and the mean time to peak effect for both doses was approximately 1.5 hours after 4 weeks of treatment. The mean duration of effect, as measured by a &gt;15% increase from baseline FEV<span class="Sub">1</span>, was approximately 5 hours after administration of 0.63 mg of levalbuterol and approximately 6 hours after administration of 1.25 mg of levalbuterol after 4 weeks of treatment. In some patients, the duration of effect was as long as 8 hours.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold">Children 6-11 Years Old</span></p>
<p>A multicenter, randomized, double-blind, placebo- and active-controlled study was conducted in children with mild-to-moderate <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> (mean baseline FEV<span class="Sub">1</span> 73% of predicted) (n=316). Following a 1-week placebo run-in, subjects were randomized to XOPENEX (0.31 or 0.63 mg), racemic albuterol (1.25 or 2.5 mg), or placebo, which were delivered three times a day for 3 weeks using a PARI LC Plus™ nebulizer and a Dura-Neb<span class="Sup">®</span> 3000 compressor.
</p>
<p>Efficacy, as measured by mean peak percent change from baseline FEV<span class="Sub">1</span>, was demonstrated for all active treatment regimens compared with placebo on day 1 and day 21. Time profile FEV<span class="Sub">1</span> curves for day 1 and day 21 are shown in <a href="#fig3">Figure 3</a> and <a href="#fig4">Figure 4</a>, respectively. The onset of effect (time to a 15% increase in FEV<span class="Sub">1</span> over test-day baseline) and duration of effect (maintenance of a &gt;15% increase in FEV<span class="Sub">1</span> over test-day baseline) of levalbuterol were clinically comparable to those of racemic albuterol.
</p>
<p><a name="fig3"></a><span class="Bold">Figure 3:  Mean Percent Change from Baseline FEV</span><span class="Bold"><span class="Sub">1</span> on Day 1, Children 6-11 Years of Age</span></p>
<div class="Figure">
<a name="f04"></a><img alt="Figure 3
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-04.jpg">
</div>
<p><a name="fig4"></a><span class="Bold">Figure 4:  Mean Percent Change from Baseline FEV</span><span class="Bold"><span class="Sub">1</span> on Day 21, Children 6-11 Years of Age</span></p>
<div class="Figure">
<a name="f05"></a><img alt="Figure 4
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-05.jpg">
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s54"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">XOPENEX Inhalation Solution is supplied in 3 mL unit-dose, low-density polyethylene (LDPE) vials as a clear, colorless, sterile, preservative-free, aqueous solution, in three different strengths of levalbuterol (0.31 mg, 0.63 mg, 1.25 mg). Each strength of XOPENEX Inhalation Solution is available in a shelf-carton containing one or more foil pouches, each containing 12 unit-dose LDPE vials.
</p>
<p><span class="Bold">XOPENEX (levalbuterol HCl) Inhalation Solution, 0.31 mg
</span><span class="Italics">(foil pouch label color green)</span> contains 0.31 mg of levalbuterol (as 0.36 mg of levalbuterol HCl) and is available in cartons of 24 unit-dose LDPE vials (NDC 17478-172-24).
</p>
<p><span class="Bold">XOPENEX (levalbuterol HCl) Inhalation Solution, 0.63 mg
</span><span class="Italics">(foil pouch label color yellow)</span> contains 0.63 mg of levalbuterol (as 0.73 mg of levalbuterol HCl) and is available in cartons of 24 unit-dose LDPE vials (NDC 17478-173-24).
</p>
<p><span class="Bold">XOPENEX (levalbuterol HCl) Inhalation Solution, 1.25 mg
</span><span class="Italics">(foil pouch label color red)</span> contains 1.25 mg of levalbuterol (as 1.44 mg of levalbuterol HCl) and is available in cartons of 24 unit-dose LDPE vials (NDC 17478-174-24).
</p>
<p>XOPENEX Inhalation Solution is also available as a concentrate in individually pouched 0.5 mL unit-dose vials containing 1.25 mg of levalbuterol (NDC 17478-171-30).
</p>
<p>Store XOPENEX Inhalation Solution in the protective foil pouch at 20 to 25°C (68 to 77°F) [see USP Controlled Room Temperature]. Protect from light and excessive heat. Keep unopened vials in the foil pouch. Once the foil pouch is opened, the vials should be used within 2 weeks. Vials removed from the pouch, if not used immediately, should be protected from light and used within 1 week. Discard any vial if the solution is not colorless.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s55"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<p class="First">See FDA-approved patient labeling (<a href="#s63">Patient Information</a> and <a href="#s64">Instructions for Using XOPENEX Inhalation Solution</a>).
</p>
<p>Patients should be given the following information:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></p>
<p>Query patients about previously experienced <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levalbuterol or racemic albuterol and counsel patients to report any <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to their physician.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-15.2"></a><p></p>
<p class="First"><span class="Underline">Frequency of Use</span></p>
<p>Inform patients not to increase the dose or use XOPENEX Inhalation Solution more frequently than recommended without consulting their physician. If patients find that treatment with XOPENEX Inhalation Solution becomes less effective for symptomatic relief, symptoms become worse, or they need to use the product more frequently than usual, they should seek medical attention immediately.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-15.3"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">Paradoxical Bronchospasm</span></span></p>
<p>Inform patients that XOPENEX Inhalation Solution can produce <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span>. Instruct patients to discontinue XOPENEX Inhalation Solution if <span class="product-label-link" type="condition" conceptid="4010475" conceptname="Paradoxical bronchospasm">paradoxical bronchospasm</span> occurs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-15.4"></a><p></p>
<p class="First"><span class="Underline">Concomitant Drug Use</span></p>
<p>Inform patients using XOPENEX Inhalation Solution, that other inhaled drugs and <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medications should be taken only as directed by their physician.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-15.5"></a><p></p>
<p class="First"><span class="Underline">Common Adverse Reactions</span></p>
<p>Advise patients of the common adverse reactions of treatment with XOPENEX Inhalation Solution including <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, fast heart rate, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-15.6"></a><p></p>
<p class="First"><span class="Underline">Pregnancy</span></p>
<p>Advise patients who are pregnant or nursing to contact their physician about the use of XOPENEX Inhalation Solution.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-15.7"></a><p></p>
<p class="First"><span class="Underline">General Information on Storage and Use</span></p>
<p>Advise patients to store XOPENEX Inhalation Solution in the foil pouch between 20°C to 25°C (68°F to 77°F) protected from light and excessive heat. Do not use after the expiration date stamped on the container. Store unused vials in the protective foil pouch. Once the foil pouch is opened, use the vials within 2 weeks.  Use vials removed from the pouch, immediately, or protect from light and use within 1 week. Discard any vial if the solution is not colorless.
</p>
<p>Advise patients not to mix XOPENEX Inhalation Solution with other drugs in a nebulizer.
</p>
<p><span class="Bold">AKORN<br></span>Distributed by: <span class="Bold">Akorn, Inc.<br></span>Lake Forest, IL 60045
</p>
<p>Manufactured for: <span class="Bold">Oak Pharmaceuticals, Inc.</span></p>
<p>For customer service, call 1-800-932-5676.<br>To report adverse events, call 1-800-932-5676.<br>For medical information, call 1-800-932-5676.
</p>
<p>Xopenex is a registered trademark of Sunovion Pharmaceuticals Inc. and is used under license.
</p>
<p>XP00N        January 2015<br>AKNX024-642R00
</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="s63"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p><span class="Bold">XOPENEX</span><span class="Bold"><span class="Sup">®</span></span>(pronounced z?-pen-eks)
</p>
<p><span class="Bold">(levalbuterol hydrochloride)</span></p>
<p><span class="Bold">Inhalation Solution</span></p>
<p><span class="Bold">0.31 mg, 0.63 mg, 1.25 mg</span></p>
<p><span class="Bold">3 mL Unit-Dose Vials</span></p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<span class="Bold">For Oral Inhalation Only</span><br><span class="Bold">XOPENEX Inhalation Solution is only for use with a nebulizer.</span>
</td></tr></tbody>
</table>
<p>Read this Patient Information before you start to use XOPENEX Inhalation Solution and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment.
</p>
<p><span class="Bold">What is XOPENEX Inhalation Solution?</span></p>
<p>XOPENEX Inhalation Solution is an inhaled prescription medicine used for the treatment or prevention of <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in people 6 years of age and older.
</p>
<p>XOPENEX Inhalation Solution has not been shown to be safe and effective in children younger than 6 years of age.
</p>
<p>XOPENEX Inhalation Solution is supplied in 3 mL unit-dose vials in three different strengths of levalbulterol (0.31 mg, 0.63 mg, 1.25 mg). The vials do not require dilution before use.
</p>
<p><span class="Bold">Who should not use XOPENEX Inhalation Solution?</span></p>
<p><span class="Bold">Do not use XOPENEX Inhalation Solution if you</span> are allergic to levalbuterol, racemic albuterol, or any of the ingredients in XOPENEX. See the end of this leaflet for a complete list of ingredients in XOPENEX Inhalation Solution.
</p>
<p><span class="Bold">What should I tell my doctor before using XOPENEX Inhalation Solution?</span></p>
<p><span class="Bold">Before you use XOPENEX Inhalation Solution, tell your doctor if you have:</span></p>
<ul class="Disc">
<li>had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to levalbuterol or racemic albuterol
</li>
<li>heart problems
</li>
<li>high blood pressure
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>
</li>
<li>thyroid problems
</li>
<li>any other medical conditions
</li>
<li>are pregnant or planning to become pregnant. It is not known if XOPENEX Inhalation Solution will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.
</li>
<li>are breastfeeding or plan to breastfeed. It is not known if XOPENEX Inhalation Solution passes into your breast milk. You and your doctor should decide if you will use XOPENEX Inhalation Solution or breastfeed. You should not do both.
</li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take</span> including prescription and over-the-counter medicines, vitamins, and herbal supplements. XOPENEX Inhalation Solution may affect the way other medicines work, and other medicines may affect how XOPENEX Inhalation Solution works.
</p>
<p>Especially tell your doctor if you take:
</p>
<ul class="Disc">
<li>other <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> medicines
</li>
<li>heart medicines
</li>
<li>medicines that increase urination (diuretics)
</li>
<li>antidepressants
</li>
<li>medicine to treat <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>)
</li>
</ul>
<p>Ask your doctor if you are not sure if any of your medicines are the kinds listed above.
</p>
<p>Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.
</p>
<p><span class="Bold">How should I use XOPENEX Inhalation Solution?</span></p>
<ul class="Disc">
<li>Read the step-by-step <a href="#s64">Instructions for Using XOPENEX Inhalation Solution</a> at the end of this leaflet.
</li>
<li>Use XOPENEX Inhalation Solution exactly as your doctor tells you to. <span class="Bold">Do not</span> change your dose without talking to your doctor first.
</li>
<li>Your doctor will tell you how many times and when to use your XOPENEX Inhalation Solution.
</li>
<li>An adult should help a child use XOPENEX Inhalation Solution.
</li>
<li><span class="Bold">Do not use your XOPENEX Inhalation Solution more often than your doctor tells you to.</span></li>
<li>
<span class="Bold">Get medical help right away if XOPENEX Inhalation Solution:</span><ul class="Circle">
<li>does not work as well for your <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms or
</li>
<li>your <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> symptoms get worse or
</li>
<li>you need to use your XOPENEX Inhalation Solution more often than usual
</li>
</ul>
</li>
<li>If you also use another medicine by inhalation, you should ask your doctor for instructions on when to use it while you are also using XOPENEX Inhalation Solution.
</li>
<li>
<span class="Bold">Do not</span> mix XOPENEX Inhalation Solution with other medicines in your nebulizer.
</li>
<li>
<span class="Bold">Only use XOPENEX Inhalation Solution if it is colorless.</span> Throw away the XOPENEX Inhalation Solution vial if the liquid medicine is not colorless.
</li>
<li>Do not use XOPENEX Inhalation Solution after the expiration date on the vial.
</li>
</ul>
<p><span class="Bold">What are the possible side effects of XOPENEX Inhalation Solution?</span></p>
<p><span class="Bold">XOPENEX Inhalation Solution can cause serious side effects including:</span></p>
<ul class="Disc">
<li>
<span class="Bold">sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> (<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>).</span> Sudden <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> can happen right away after using XOPENEX Inhalation Solution.
</li>
<li><span class="Bold">worsening <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></span></li>
<li><span class="Bold">heart problems</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> If you use too much XOPENEX Inhalation Solution you can have heart or lung problems that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
</li>
<li>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</span> Call your doctor and stop using XOPENEX Inhalation Solution right away if you have any symptoms of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> such as:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, throat or tongue
</li>
<li><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>
</li>
<li>breathing problems
</li>
</ul>
</li>
<li><span class="Bold">low potassium levels in your blood</span></li>
</ul>
<p>Call your doctor or go to the nearest hospital emergency room right away if you have any of the serious side effects listed above or if you have worsening lung symptoms.
</p>
<p><span class="Bold">The most common side effects of XOPENEX Inhalation Solution include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>
</li>
<li>fast heart rate
</li>
<li><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>
</li>
</ul>
<p>Tell your doctor if you have any side effects that bother you or that do not go away.
</p>
<p>These are not all the possible side effects of XOPENEX Inhalation Solution. For more information, ask your doctor or pharmacist.
</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">How should I store XOPENEX Inhalation Solution?</span></p>
<ul class="Disc">
<li>Store unopened XOPENEX Inhalation Solution vials in the protective foil pouch they come in between 68°F to 77°F (20°C to 25°C).
</li>
<li>Keep XOPENEX Inhalation Solution away from light and heat.
</li>
<li>When a XOPENEX Inhalation Solution foil pouch is opened, use the vials within 2 weeks.
</li>
<li>When XOPENEX Inhalation Solution vials are removed from the foil pouch, use them right away or within 1 week.
</li>
</ul>
<p><span class="Bold">Keep XOPENEX Inhalation Solution and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of XOPENEX Inhalation Solution.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use XOPENEX Inhalation Solution for a condition for which it was not prescribed. Do not give XOPENEX Inhalation Solution to other people, even if they have the same symptoms that you have. It may harm them.
</p>
<p>This Patient Information leaflet summarizes the most important information about XOPENEX Inhalation Solution. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about XOPENEX Inhalation Solution that is written for health professionals.
</p>
<p>For customer service, call 1-800-932-5676.<br>To report adverse events, call 1-800-932-5676.<br>For medical information, call 1-800-932-5676.
</p>
<p><span class="Bold">What are the ingredients in XOPENEX Inhalation Solution?</span></p>
<p>Active ingredient: levalbuterol hydrochloride
</p>
<p>Inactive ingredients: sodium chloride, sulfuric acid, water and nitrogen
</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="s64"></a><a name="section-17"></a><p></p>
<table width="100%">
<col align="left" width="100.000%">
<tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><span class="Bold">Instructions for Using XOPENEX Inhalation Solution</span></td></tr></tbody>
</table>
<p class="First"><span class="Bold">XOPENEX Inhalation Solution vial (see <a href="#f06">Figure A</a>):</span></p>
<div class="Figure">
<a name="f06"></a><img alt="Figure A
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-06.jpg">
</div>
<p><span class="Bold">Using your XOPENEX Inhalation Solution:</span></p>
<p><span class="Bold">Read the following Steps before</span> using your XOPENEX Inhalation Solution. If you have any questions, ask your doctor or pharmacist.
</p>
<p><span class="Bold">Step 1.</span> Open the foil pouch by tearing the notched edge along the seam of the pouch (<span class="Bold">See <a href="#f07">Figure B</a></span>). Remove 1 vial to be used right away. Keep the rest of the unused vials in the foil pouch to protect them from light and heat.
</p>
<div class="Figure">
<a name="f07"></a><img alt="Figure B
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-07.jpg">
</div>
<p><span class="Bold">Step 2.</span> Hold the vial in your hands. Make sure your thumb and finger cover the twist-off tabs below the X-top (<span class="Bold">See <a href="#f08">Figure C</a></span>).
</p>
<div class="Figure">
<a name="f08"></a><img alt="Figure C
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-08.jpg">
</div>
<p><span class="Bold">Step 3.</span> While holding the top firmly between your thumb and finger, twist the body of the vial to open the vial (<span class="Bold">See <a href="#f08">Figure C</a></span>).
</p>
<p><span class="Bold">Step 4.</span> Throw away the top of the vial and squeeze the entire contents of the vial into the nebulizer reservoir (<span class="Bold">See <a href="#f09">Figure D</a></span>).
</p>
<div class="Figure">
<a name="f09"></a><img alt="Figure D
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-09.jpg">
</div>
<p><span class="Bold">Step 5.</span> Connect the nebulizer reservoir to the mouthpiece (<span class="Bold">See <a href="#f10">Figure E.1</a></span>) or face mask (<span class="Bold">See <a href="#f10">Figure E.2</a></span>).
</p>
<div class="Figure">
<a name="f10"></a><img alt="Figures E.1 and E.2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-10.jpg">
</div>
<p><span class="Bold">Step 6.</span> Connect the nebulizer to the compressor (<span class="Bold">See <a href="#f11">Figure F</a></span>).
</p>
<div class="Figure">
<a name="f11"></a><img alt="Figure F
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-11.jpg">
</div>
<p><span class="Bold">Step 7.</span> Sit in a comfortable, upright position. Place the mouthpiece in your mouth (<span class="Bold">See <a href="#f12">Figure G.1</a></span>) or put on your face mask (<span class="Bold">See <a href="#f12">Figure G.2</a></span>). Turn on the compressor.
</p>
<div class="Figure">
<a name="f12"></a><img alt="Figures G.1 and G.2
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-12.jpg">
</div>
<p><span class="Bold">Step 8.</span> Breathe as calmly, deeply, and evenly as possible until no more mist is seen in the nebulizer reservoir. Your treatment will take about 5 to 15 minutes. When you do not see any mist in the nebulizer reservoir, your treatment is finished.
</p>
<p><span class="Bold">Step 9.</span> Clean and store your nebulizer. See the manufacturer's instructions that come with your nebulizer for how to clean and store your nebulizer.
</p>
<p>This Patient Information and Instructions for Use have been approved by the U.S. Food and Drug Administration.
</p>
<p><span class="Bold">AKORN<br></span>Distributed by: <span class="Bold">Akorn, Inc.<br></span>Lake Forest, IL 60045
</p>
<p>Manufactured for: <span class="Bold">Oak Pharmaceuticals, Inc.</span></p>
<p>For customer service, call 1-800-932-5676.<br>To report adverse events, call 1-800-932-5676.<br>For medical information, call 1-800-932-5676.
</p>
<p>Xopenex is a registered trademark of Sunovion Pharmaceuticals Inc. and is used under license.
</p>
<p>XP00N     January 2015<br>AKNX024-642R00
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s65"></a><a name="section-18"></a><p></p>
<p class="First">Principal Display Panel Text for Pouch Label:
</p>
<p>Xopenex® NDC 17478-172-12
</p>
<p>(levalbuterol HCl)
</p>
<p>Inhalation Solution 0.31 mg/3 mL*  *Potency expressed as levalbuterol
</p>
<div class="Figure">
<a name="f13"></a><img alt="Principal Display Panel Text for Pouch Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-13.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s66"></a><a name="section-19"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-172-24
</p>
<p>0.31 mg/3 mL
</p>
<p>Xopenex®
</p>
<p>(levalbuterol HCl)  *Potency expressed as levalbuterol
</p>
<p>Inhalation Solution  For Oral Inhalation Only. Sterile Unit-Dose Vial
</p>
<p>0.31 mg/3 mL*  24 x 3 mL Sterile Unit-Dose Vials
</p>
<p>Rx only
</p>
<p>Akorn Logo
</p>
<div class="Figure">
<a name="f14"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-14.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s67"></a><a name="section-20"></a><p></p>
<p class="First">Principal Display Panel Text for Pouch Label:
</p>
<p>Xopenex® NDC 17478-173-12
</p>
<p>(levalbuterol HCl)
</p>
<p>Inhalation Solution 0.63 mg/3 mL*  *Potency expressed as levalbuterol
</p>
<div class="Figure">
<a name="f15"></a><img alt="Principal Display Panel Text for Pouch Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-15.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s68"></a><a name="section-21"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-173-24
</p>
<p>0.63 mg/3 mL
</p>
<p>Xopenex®
</p>
<p>(levalbuterol HCl)  *Potency expressed as levalbuterol
</p>
<p>Inhalation Solution  For Oral Inhalation Only. Sterile Unit-Dose Vial
</p>
<p>0.63 mg/3 mL*  24 x 3 mL Sterile Unit-Dose Vials
</p>
<p>Rx only
</p>
<p>Akorn Logo
</p>
<div class="Figure">
<a name="f16"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-16.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s69"></a><a name="section-22"></a><p></p>
<p class="First">Principal Display Panel Text for Pouch Label:
</p>
<p>Xopenex® NDC 17478-174-12
</p>
<p>(levalbuterol HCl)
</p>
<p>Inhalation Solution 1.25 mg/3 mL*  *Potency expressed as levalbuterol
</p>
<div class="Figure">
<a name="f17"></a><img alt="Principal Display Panel Text for Pouch Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-17.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s70"></a><a name="section-23"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 17478-174-24
</p>
<p>1.25 mg/3 mL
</p>
<p>Xopenex®
</p>
<p>(levalbuterol HCl)  *Potency expressed as levalbuterol
</p>
<p>Inhalation Solution  For Oral Inhalation Only. Sterile Unit-Dose Vial
</p>
<p>1.25 mg/3 mL*  24 x 3 mL Sterile Unit-Dose Vials
</p>
<p>Rx only
</p>
<p>Akorn Logo
</p>
<div class="Figure">
<a name="f18"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7e2644e6-36c5-4988-8e52-bec90e2cd2f0&amp;name=xop07-0000-18.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XOPENEX 		
					</strong><br><span class="contentTableReg">levalbuterol hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-172</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Levalbuterol Hydrochloride</strong> (Levalbuterol) </td>
<td class="formItem">Levalbuterol</td>
<td class="formItem">0.31 mg  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sulfuric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-172-24</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-172-12</td>
<td class="formItem">12  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020837</td>
<td class="formItem">02/27/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XOPENEX 		
					</strong><br><span class="contentTableReg">levalbuterol hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-173</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Levalbuterol Hydrochloride</strong> (Levalbuterol) </td>
<td class="formItem">Levalbuterol</td>
<td class="formItem">0.63 mg  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sulfuric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-173-24</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-173-12</td>
<td class="formItem">12  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020837</td>
<td class="formItem">02/27/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>XOPENEX 		
					</strong><br><span class="contentTableReg">levalbuterol hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:17478-174</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RESPIRATORY (INHALATION)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Levalbuterol Hydrochloride</strong> (Levalbuterol) </td>
<td class="formItem">Levalbuterol</td>
<td class="formItem">1.25 mg  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sulfuric Acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Nitrogen</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-174-24</td>
<td class="formItem">2  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:17478-174-12</td>
<td class="formItem">12  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020837</td>
<td class="formItem">02/27/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akorn, Inc.
							(062649876)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fb96eca6-a94c-4baa-8156-9a1395ead5db</div>
<div>Set id: 7e2644e6-36c5-4988-8e52-bec90e2cd2f0</div>
<div>Version: 1</div>
<div>Effective Time: 20150227</div>
</div>
</div> <div class="DistributorName">Akorn, Inc.</div></p>
</body></html>
